Pfizer DMD Gene Therapy Phase III Trial Faces A US Delay; Can Sarepta Close The Gap?

Sarepta Hopes To Meet With FDA Midyear

Pfizer disclosed that a Phase III trial for the gene therapy has been unable to start in the US because of questions from the FDA, even while enrollment in 15 sites outside the US is under way.

Boat Race
Pfizer and Sarepta are in a race to develop a DMD gene therapy • Source: Alamy

Pfizer Inc., which has taken the lead in the race to bring the first gene therapy to market for Duchenne muscular dystrophy (DMD), has faced a delay with the start of a Phase III trial in the US, presenting an opportunity for Sarepta Therapeutics, Inc. to close the gap with its rival gene therapy, SRP-9001.

Pfizer has been the first to advance its gene therapy candidate – fordadistrogene movaparvovec – into Phase III clinical development,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies